INGELHEIM, Germany--(BUSINESS WIRE)--For media excluding US/Canada and UK Boehringer Ingelheim announced data which add to the growing body of evidence that show ...
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO ® 1&2 trials (NCT01964352 ...
Boehringer Ingelheim's COPD treatment, Spiolto Respimat, is up against a raft of competitors--especially in the EU, where it recently won its first approvals. Now, though, it's touting new data from a ...
Boehringer Ingelheim today announced new data from two trials presented at the European Respiratory Society (ERS) International Congress 2015. A posthoc analysis from OTEMTO® 1&2 indicates that ...
GlaxoSmithKline and Innoviva say their combination lung therapy Anoro Ellipta has come out on top in a trial pitting its effectiveness in improving lung function against that of Boehringer Ingelheim’s ...
Boehringer Ingelheim's recently-approved Spiolto is more effective than GlaxoSmithKline's Seretide/Advair in improving lung function in patients with chronic obstructive pulmonary disease (COPD), ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Spiolto Respimat contains the active ingredients tiotropium (as ...
A Spiriva-based combination therapy that Boehringer Ingelheim believes will consolidate its position in the chronic obstructive pulmonary disease (COPD) market has been cleared for marketing in nine ...
In COPD, quality of life is measured using the SGRQ†; a reduction in SGRQ score of 4 points or more is deemed clinically meaningful.2 The OTEMTO® trials show Spiolto® Respimat® provides a reduction in ...
“It is of paramount importance that people with COPD remain as active as possible to minimise the impact of the disease on their daily lives,” said Professor Thierry Troosters, Head of the Research ...
Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO ® 1&2 trials (NCT01964352/NCT02006732), which show Spiolto ® Respimat ...
OTEMTO trials show Spiolto Respimat provides clinically meaningful >4 point reduction in SGRQ score compared to placebo i The results underline the benefit Spiolto Respimat can bring to the daily life ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results